Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?

Kerr KM, Hirsch FR.

Arch Pathol Lab Med. 2016 Apr;140(4):326-31. doi: 10.5858/arpa.2015-0522-SA. Epub 2016 Jan 12.

PMID:
26756647
2.

Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.

Kerr KM, Nicolson MC.

Arch Pathol Lab Med. 2016 Mar;140(3):249-54. doi: 10.5858/arpa.2015-0303-SA. Review.

PMID:
26927720
3.

Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?

Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba II, Hirsch FR; IASLC Pathology Committee.

J Thorac Oncol. 2015 Jul;10(7):985-9. doi: 10.1097/JTO.0000000000000526. Review.

4.

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.

Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, Li X, Jin X, Steele KE, Robbins PB, Blake-Haskins JA, Walker J.

Diagn Pathol. 2016 Oct 8;11(1):95.

5.

[PD-L1 expression: An emerging biomarker in non-small cell lung cancer].

Adam J, Planchard D, Marabelle A, Soria JC, Scoazec JY, Lantuéjoul S.

Ann Pathol. 2016 Jan;36(1):94-102. doi: 10.1016/j.annpat.2015.11.004. Epub 2016 Jan 14. French.

PMID:
26778219
6.

Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.

Sholl LM, Aisner DL, Allen TC, Beasley MB, Borczuk AC, Cagle PT, Capelozzi V, Dacic S, Hariri L, Kerr KM, Lantuejoul S, Mino-Kenudson M, Raparia K, Rekhtman N, Roy-Chowdhuri S, Thunnissen E, Tsao MS, Yatabe Y; Members of Pulmonary Pathology Society.

Arch Pathol Lab Med. 2016 Apr;140(4):341-4. doi: 10.5858/arpa.2015-0506-SA. Epub 2016 Jan 18.

PMID:
26780537
7.

Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.

Tokito T, Azuma K, Kawahara A, Ishii H, Yamada K, Matsuo N, Kinoshita T, Mizukami N, Ono H, Kage M, Hoshino T.

Eur J Cancer. 2016 Mar;55:7-14. doi: 10.1016/j.ejca.2015.11.020. Epub 2016 Jan 6.

PMID:
26771872
8.

[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].

Scheel AH, Dietel M, Heukamp LC, Jöhrens K, Kirchner T, Reu S, Rüschoff J, Schildhaus HU, Schirmacher P, Tiemann M, Warth A, Weichert W, Fischer RN, Wolf J, Büttner R.

Pathologe. 2016 Nov;37(6):557-567. Review. German.

PMID:
27510417
9.

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.

Sul J, Blumenthal GM, Jiang X, He K, Keegan P, Pazdur R.

Oncologist. 2016 May;21(5):643-50. doi: 10.1634/theoncologist.2015-0498. Epub 2016 Mar 29.

10.

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.

McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL.

JAMA Oncol. 2016 Jan;2(1):46-54. doi: 10.1001/jamaoncol.2015.3638. Erratum in: JAMA Oncol. 2016 Jan;2(1):146.

11.

Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.

Remon J, Chaput N, Planchard D.

Curr Opin Oncol. 2016 Mar;28(2):122-9. doi: 10.1097/CCO.0000000000000263. Review.

PMID:
26756384
12.

PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation.

Cree IA, Booton R, Cane P, Gosney J, Ibrahim M, Kerr K, Lal R, Lewanski C, Navani N, Nicholson AG, Nicolson M, Summers Y.

Histopathology. 2016 Aug;69(2):177-86. doi: 10.1111/his.12996. Epub 2016 Jun 30. Review. Erratum in: Histopathology. 2017 Jan;70(2):318.

13.

Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue.

Dolled-Filhart M, Locke D, Murphy T, Lynch F, Yearley JH, Frisman D, Pierce R, Weiner R, Wu D, Emancipator K.

Arch Pathol Lab Med. 2016 Nov;140(11):1259-1266.

PMID:
27788043
14.

Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.

Sheffield BS, Fulton R, Kalloger SE, Milne K, Geller G, Jones M, Jacquemont C, Zachara S, Zhao E, Pleasance E, Laskin J, Jones SJ, Marra MA, Yip S, Nelson BH, Gown AM, Ho C, Ionescu DN.

J Histochem Cytochem. 2016 Oct;64(10):587-600. doi: 10.1369/0022155416665338. Epub 2016 Sep 2.

15.

Challenges to Biomarker Testing for PD-1/PD-L1 Checkpoint Inhibitors for Lung Cancer.

Cagle PT, Bernicker EH.

Arch Pathol Lab Med. 2015 Dec;139(12):1477-8. doi: 10.5858/arpa.2015-0902-ED. No abstract available.

PMID:
26619015
16.

PD-L1 and Lung Cancer: The Era of Precision-ish Medicine?

Borczuk AC, Allen TC.

Arch Pathol Lab Med. 2016 Apr;140(4):351-4. doi: 10.5858/arpa.2015-0509-SA. Epub 2016 Jan 12.

PMID:
26756646
17.

Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.

Lin C, Chen X, Li M, Liu J, Qi X, Yang W, Zhang H, Cai Z, Dai Y, Ouyang X.

Clin Lung Cancer. 2015 Sep;16(5):e25-35. doi: 10.1016/j.cllc.2015.02.002. Epub 2015 Feb 19.

PMID:
25801750
18.

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.

Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, Yip P, Yu B, O'Toole SA, McCaughan BC, Yearley JH, Horvath LG, Kao S, Boyer M, Scolyer RA.

Lung Cancer. 2015 Aug;89(2):181-8. doi: 10.1016/j.lungcan.2015.05.007. Epub 2015 May 18.

PMID:
26024796
19.

Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer.

Sheng J, Fang W, Yu J, Chen N, Zhan J, Ma Y, Yang Y, Huang Y, Zhao H, Zhang L.

Sci Rep. 2016 Jan 29;6:20090. doi: 10.1038/srep20090. Erratum in: Sci Rep. 2016;6:23850. Yanhuang, [corrected to Huang, Yan].

20.

Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.

Kim S, Kim MY, Koh J, Go H, Lee DS, Jeon YK, Chung DH.

Eur J Cancer. 2015 Nov;51(17):2698-707. doi: 10.1016/j.ejca.2015.08.013. Epub 2015 Aug 29.

PMID:
26329973

Supplemental Content

Support Center